ReviewAdvances in therapy2020
Iron Sucrose: A Wealth of Experience in Treating Iron Deficiency.
Review in Advances in therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 28 citations in OpenAlex.
- Analyzing Molecular Determinants of Nanodrugs' Cytotoxic Effects.International journal of molecular sciences · 2025Pooled it
- Efficacy, Safety, and Tolerability of Ferric Carboxymaltose and Iron Sucrose in Iron-Deficiency Anemia: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsTurkish journal of haematology : official journal of Turkish Society of Haematology · 2025Pooled it
- Effect of food on iron absorption in patients with iron deficiency anemia treated with ferric citrate hydrate.International journal of hematology · 2026Trial
- When Iron Bites Back: Severe Thrombocytopenia After Intravenous Iron Sucrose Therapy (Venofer).Cureus · 2026Article
- Effectiveness of Plan-Do-Check-Act Approach in Improving Patient Satisfaction and Quality of Care in Parenteral Iron Deficiency Treatment.Global journal on quality and safety in healthcare · 2026Article
- An Updated Review on Iron Deficiency Anemia: From Epidemiology to Diagnosis, Etiology, Prevention and Treatment.Journal of blood medicine · 2026Review
- Intravenously administered iron oxide nanoparticles with different coatings reversibly perturb immune cells in peripheral blood without inducing toxicity in mice.Frontiers in toxicology · 2025Article
- Article
- Article
- Iron nanoparticles as food additives and food supplements, regulatory and legislative perspectives.Food science and biotechnology · 2024Review
- [The efficacy and safety of intravenous sucrose iron therapy for recurrent iron deficiency anemia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2023Article
- Probing Subcellular Iron Availability with Genetically Encoded Nitric Oxide Biosensors.Biosensors · 2022Article
- Criticality of Surface Characteristics of Intravenous Iron-Carbohydrate Nanoparticle Complexes: Implications for Pharmacokinetics and Pharmacodynamics.International journal of molecular sciences · 2022Review
- Development of Pharmaceutical Nanomedicines: From the Bench to the Market.Pharmaceutics · 2022Review
- Effect of Iron-Erythrocyte Metabolism-Related Indexes on Posttraumatic Growth in Patients on Maintenance Hemodialysis (MHD).International journal of general medicine · 2022Article
- Current Status of Renal Anemia Pharmacotherapy-What Can We Offer Today.Journal of clinical medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 5 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Iron deficiency and iron-deficiency anemia are associated with increased morbidity and mortality in a wide range of conditions. In many patient populations, this can be treated effectively with oral iron supplementation; but in patients who are unable to take or who do not respond to oral iron therapy, intravenous iron administration is recommended. Furthermore, in certain conditions, such as end-stage kidney disease, chronic heart failure, and inflammatory bowel disease, intravenous iron administration has become first-line treatment. One of the first available intravenous iron preparations is iron sucrose (Venofer
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.